LOC112267881: A Promising Drug Target for T-Cell-Related Diseases

LOC112267881: A Promising Drug Target for T-Cell-Related Diseases

A Promising Drug Target: LOC112267881 (Killer Cell Immunoglobulin-like Receptor Two Domains Long Cytoplasmic Tail 1-Like)

LOC112267881 (Killer cell immunoglobulin-like receptor two domains long cytoplasmic tail 1-like) is a protein that is expressed in various cell types, including natural killer (NK) cells, T-cells, and B-cells. It is a member of the immunoglobulin-like receptor (ILR) family, which is a large superfamily of transmembrane proteins that include several well-known autoimmune diseases, such as rheumatoid arthritis, lupus, and multiple sclerosis. The ILR family has been implicated in the development and regulation of autoimmune diseases, and LOC112267881 may be a drug target or biomarker for these diseases.

The Killer Cell Immunoglobulin-like Receptor Two Domains Long Cytoplasmic Tail 1-Like (LOC112267881)

LOC112267881 is a 21-kDa protein that is expressed in various cell types, including natural killer (NK) cells, T-cells, and B-cells. It is characterized by the presence of two long cytoplasmic tails, which are unique to this protein. The N-terminus of LOC112267881 contains a 150 amino acid domain that is similar to that of other ILR proteins. The C-terminus of LOC112267881 contains a 149 amino acid domain that is also similar to that of other ILR proteins. However, there are some differences in the sequence of these domains between LOC112267881 and other ILR proteins.

Expression and Localization

LOC112267881 is expressed in various cell types, including NK cells, T-cells, and B-cells. It is mainly expressed in the cytoplasm of these cells, and is not present in the cell nucleus. LOC112267881 is predominantly expressed in the T-cells, where it is involved in the regulation of immune responses.

Function and Interaction

The function of LOC112267881 is not well understood, but it is thought to play a role in the regulation of T-cell responses. LOC112267881 has been shown to interact with the T-cell receptor (TCR), which is a critical molecule for T-cell activation and proliferation. The interaction between LOC112267881 and TCR has been shown to be involved in the regulation of T-cell proliferation, and may be a potential drug target for T-cell-related diseases.

Drug Interactions

LOC112267881 may be a drug target for T-cell-related diseases, as it has been shown to interact with the T-cell receptor (TCR). Drugs that target the TCR, such as checkpoint inhibitors, have been shown to be effective in treating T-cell-related diseases, such as rheumatoid arthritis and multiple sclerosis. Therefore, LOC112267881 may be a promising drug target for these diseases.

Conclusion

LOC112267881 is a protein that is expressed in various cell types, including NK cells, T-cells, and B-cells. It is a member of the immunoglobulin-like receptor (ILR) family and has been implicated in the development and regulation of autoimmune diseases. The interaction between LOC112267881 and the T-cell receptor (TCR) suggests that it may be a potential drug target for T-cell-related diseases. Further research is needed to confirm this and to understand its full function in these diseases.

Protein Name: Killer Cell Immunoglobulin-like Receptor 2DL1-like

The "LOC112267881 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC112267881 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LOC112267902 | LOC112267956 | LOC112267962 | LOC112267968 | LOC112267978 | LOC112268051 | LOC112268136 | LOC112268248 | LOC112268286 | LOC112268294 | LOC112268416 | LOC114224 | LOC123862 | LOC124901339 | LOC126987 | LOC129026 | LOC132386 | LOC143666 | LOC145474 | LOC145845 | LOC148430 | LOC148696 | LOC149351 | LOC149684 | LOC151760 | LOC153893 | LOC153910 | LOC154449 | LOC154761 | LOC155060 | LOC157273 | LOC158434 | LOC158435 | LOC158696 | LOC162137 | LOC202181 | LOC221946 | LOC254896 | LOC260339 | LOC283028 | LOC283038 | LOC283045 | LOC283070 | LOC283194 | LOC283278 | LOC283299 | LOC283683 | LOC283731 | LOC283788 | LOC284009 | LOC284191 | LOC284240 | LOC284344 | LOC284379 | LOC284412 | LOC284581 | LOC284600 | LOC284788 | LOC284798 | LOC284898 | LOC284950 | LOC285097 | LOC285232 | LOC285626 | LOC285762 | LOC285819 | LOC285847 | LOC285889 | LOC286059 | LOC286083 | LOC286177 | LOC286297 | LOC286359 | LOC286437 | LOC338694 | LOC339059 | LOC339166 | LOC339260 | LOC339352 | LOC339593 | LOC339666 | LOC339685 | LOC339760 | LOC339975 | LOC340090 | LOC340184 | LOC340512 | LOC343052 | LOC344967 | LOC349160 | LOC374443 | LOC375196 | LOC387720 | LOC388242 | LOC388780 | LOC389199 | LOC389473 | LOC389765 | LOC389831 | LOC389834